Scarica l'app Stockscreener
637.36
0.24%
1.53
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Precedente Chiudi:
$635.83
Aprire:
$638.01
Volume 24 ore:
535.90K
Relative Volume:
0.62
Capitalizzazione di mercato:
$72.26B
Reddito:
$14.20B
Utile/perdita netta:
$4.41B
Rapporto P/E:
16.65
EPS:
38.28
Flusso di cassa netto:
$3.54B
1 W Prestazione:
-3.21%
1M Prestazione:
-9.31%
6M Prestazione:
-38.87%
1 anno Prestazione:
-33.78%
Intervallo 1D:
$631.45
$642.97
Intervallo di 1 settimana:
$629.02
$667.46
Portata 52W:
$629.02
$1,211.20
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Nome
Regeneron Pharmaceuticals Inc
Settore
Industria
Telefono
(914) 847-7000
Indirizzo
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Confronta REGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Downgrade | UBS | Buy → Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Iniziato | Bernstein | Outperform |
| 2024-01-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Reiterato | Oppenheimer | Perform |
| 2023-06-28 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-23 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2023-01-20 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Aggiornamento | Jefferies | Underperform → Hold |
| 2022-09-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Iniziato | Jefferies | Underperform |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-12-07 | Ripresa | Cowen | Market Perform |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Ripresa | BMO Capital Markets | Outperform |
| 2021-11-05 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-01-25 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-10-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Downgrade | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-05-26 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-17 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Iniziato | The Benchmark Company | Hold |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-11 | Aggiornamento | Argus | Hold → Buy |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-16 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Iniziato | SunTrust | Hold |
| 2019-11-07 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
Mostra tutto
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
Nomura Asset Management Co. Ltd. Has $65.90 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
1,125,933 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Bought by Norges Bank - MarketBeat
EntryPoint Capital LLC Purchases New Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Mitsubishi UFJ Asset Management Co. Ltd. Raises Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Sei Investments Co. Sells 3,371 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Hits New 12-Month LowWhat's Next? - MarketBeat
$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today - Benzinga
Sensei Biotherapeutics Reports Favorable Initial Clinical Activity Data For Solnerstotug In Resistant Tumors - Benzinga India
Regeneron (NASDAQ:REGN) and Sanofi Get Japan Green Light for Smokers’ Lung Disease Treatment - TipRanks
Loomis Sayles & Co. L P Buys 393,997 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
NEOS Investment Management LLC Purchases 4,140 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron, Sanofi Say Japan Grants Marketing Authorization for Dupixent - Marketscreener.com
Macular Degeneration Treatment Market to Witness Massive - openPR
Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD) - The Manila Times
Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with - Bluefield Daily Telegraph
Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD - GlobeNewswire
Breakthrough: Japan Approves First-Ever Biologic Treatment for COPD Patients - StockTitan
Simplify Asset Management Inc. Lowers Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
AXQ Capital LP Trims Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Mizuho Securities USA LLC Increases Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
NTLA Genome-Editing Therapy Gets FDA's RMAT Tag for New Indication - Yahoo Finance
Aviso Wealth Management Grows Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
UNIVEST FINANCIAL Corp Decreases Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Murphy & Mullick Capital Management Corp Makes New Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Mitsubishi UFJ Trust & Banking Corp Sells 5,676 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Forefront Wealth Management Inc. Takes $2.21 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Prudential Financial Inc. Sells 10,529 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Teacher Retirement System of Texas Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MSN
Regeneron Pharmaceuticals (NASDAQ:REGN) Sets New 12-Month LowHere's What Happened - MarketBeat
American Century Companies Inc. Trims Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Intellia gets FDA RMAT status for Regeneron-partnered gene editing drug - Seeking Alpha
TD Asset Management Inc. Acquires 29,322 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Decreases Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Royal London Asset Management Ltd. Purchases 409 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Advisors Asset Management Inc. Has $3.68 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by iA Global Asset Management Inc. - MarketBeat
Envestnet Portfolio Solutions Inc. Has $1.91 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
DCF Advisers LLC Increases Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Why Pharma and Biotech Stocks Got Thrashed on Tuesday - The Motley Fool
Is Regeneron Pharmaceuticals, Inc. (REGN) a Promising Biotech Stock According to Wall Street Analysts - Insider Monkey
Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025 - The Manila Times
Regeneron stock touches 52-week low at $641.91 amid market shifts By Investing.com - Investing.com South Africa
Regeneron stock touches 52-week low at $641.91 amid market shifts - Investing.com
Regeneron's Franchise Tax Claims Require Trial, NY Judge Rules - Bloomberg Tax
Is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) The Best Extremely Profitable Stocks to Buy According to Analyst? - Insider Monkey
The United States Risks Losing Its Edge in Life Sciences Innovation - Think Global Health
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Corebridge Financial Inc. - MarketBeat
Vanguard Group Inc. Cuts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Lawsuit Notice: Investors who hold Regeneron - GlobeNewswire
12 Most Promising Biotech Stocks According to Wall Street Analysts - Insider Monkey
Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Regeneron Pharmaceuticals Inc Azioni (REGN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| McCourt Marion | EVP Commercial |
Nov 01 '24 |
Option Exercise |
381.40 |
1,000 |
381,400 |
13,931 |
| McCourt Marion | EVP Commercial |
Nov 01 '24 |
Sale |
844.61 |
1,000 |
844,610 |
12,931 |
0.73%
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):